Breaking News Instant updates and real-time market news.

NVS

Novartis

$83.27

0.11 (0.13%)

05:36
07/18/17
07/18
05:36
07/18/17
05:36

Novartis backs FY17 revenue guidance of 'broadly in line with the prior year'

Novartis provided the following FY17 outlook: "We re-confirm our Group outlook as presented at the beginning of 2017. Group net sales in 2017 are expected to be broadly in line with the prior year, after absorbing the impact of generic competition, including the continued genericization of Gleevec/Glivec in the U.S. and Europe. From a divisional perspective, we expect net sales performance in 2017 to be as follows: Innovative Medicines: broadly in line with prior year, to a slight increase; Sandoz: broadly in line with prior year; Alcon: revised upward to low single digit growth. Group core operating income in 2017 is expected to be broadly in line with prior year to a low single digit decline. If mid-July exchange rates prevail for the remainder of 2017, the currency impact for the year would be negative 1 percentage point on net sales and negative 2 percentage points on core operating income."

  • 18

    Jul

NVS Novartis
$83.27

0.11 (0.13%)

07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.

TODAY'S FREE FLY STORIES

TYPE

Monotype Imaging

$18.45

-0.35 (-1.86%)

07:02
07/28/17
07/28
07:02
07/28/17
07:02
Earnings
Monotype Imaging reports Q2 adjusted EPS 8c, consensus 9c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

CMS

CMS Energy

$46.89

0.36 (0.77%)

07:01
07/28/17
07/28
07:01
07/28/17
07:01
Earnings
CMS Energy reports Q2 EPS 33c, consensus 39c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

07:01
07/28/17
07/28
07:01
07/28/17
07:01
Recommendations
Heritage Commerce analyst commentary  »

Heritage Commerce premium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

JPM

JPMorgan

$91.55

-0.38 (-0.41%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Hot Stocks
JPMorgan says to be 100% reliant on renewable energy by 2020 »

JPMorgan Chase is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

HRC

Hill-Rom

$79.70

-2.88 (-3.49%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Hill-Rom reports Q3 adj. EPS 91c, consensus 91c »

Reports Q3 revenue $689M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 06

    Aug

  • 10

    Aug

  • 15

    Aug

CFX

Colfax

$40.83

-0.12 (-0.29%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Colfax raises FY17 adjusted EPS view to $1.65-$1.75 from $1.60-$1.75 

Consensus $1.73.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

CFX

Colfax

$40.83

-0.12 (-0.29%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Colfax reports Q2 adjusted EPS 43c, consensus 43c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

DVAX

Dynavax

$9.25

-1.15 (-11.06%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Hot Stocks
Breaking Hot Stocks news story on Dynavax »

Dynavax trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 31

    Jul

  • 10

    Aug

EA

Electronic Arts

$117.60

-0.4 (-0.34%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

UFS

Domtar

$38.49

0.06 (0.16%)

06:59
07/28/17
07/28
06:59
07/28/17
06:59
Earnings
Domtar reports Q2 EPS 61c, consensus 55c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$11.83

-0.07 (-0.59%)

06:59
07/28/17
07/28
06:59
07/28/17
06:59
Periodicals
Fiat Chrysler's Maserati to launch electric model after 2019, WSJ reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$45.16

-0.57 (-1.25%)

06:57
07/28/17
07/28
06:57
07/28/17
06:57
Earnings
Valero Energy Partners reports Q2 EPS 69c, consensus 75c »

Reports Q2 revenue $110M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

ZBH

Zimmer Biomet

$125.44

-3.26 (-2.53%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
Zimmer Biomet rating change  »

Zimmer Biomet downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

JCI

Johnson Controls

$40.14

-3.18 (-7.34%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
Johnson Controls rating change  »

Johnson Controls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 08

    Aug

X

U.S. Steel

$25.00

-1.2 (-4.58%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
U.S. Steel rating change  »

U.S. Steel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.69

1.89 (3.06%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck reports Q2 KEYTRUDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

VC

Visteon

$111.53

1.56 (1.42%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Downgrade
QEP Resources rating change  »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

MRK

Merck

$63.69

1.89 (3.06%)

06:52
07/28/17
07/28
06:52
07/28/17
06:52
Hot Stocks
Merck CEO Q2 results driven by 'robust momentum for KEYTRUDA' »

"We continued to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

PLT

Plantronics

$53.65

0.15 (0.28%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Downgrade
Plantronics rating change  »

Plantronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

VLKAY

Volkswagen

$31.69

-0.66 (-2.04%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Periodicals
California approves Volkswagen's clean vehicle infrastructure plan, Reuters says »

The California Air…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSH

NuStar GP Holdings

$23.55

0.05 (0.21%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Earnings
Breaking Earnings news story on NuStar GP Holdings »

NuStar GP Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

MRK

Merck

$63.69

1.89 (3.06%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck sees FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

VFC

VF Corp.

$60.81

-0.06 (-0.10%)

06:50
07/28/17
07/28
06:50
07/28/17
06:50
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.69

1.89 (3.06%)

06:50
07/28/17
07/28
06:50
07/28/17
06:50
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck sees FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.